ArticleCell death and differentiation2026
Romboutsia ilealis related metabolite OAA controls obesity and lipid metabolism through PSMD3-mediated degradation of YTHDF2.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Gut Microbiome-Endocrine Axis in Obesity: Mechanisms and Therapeutics.Journal of gastroenterology and hepatology · 2026Review
- Effects of red palm oil intervention on serum lipids, hepatic antioxidant capacity and gut microbiota in high-fat diet-fed mice.Open life sciences · 2026Article
- Crosstalk between gut microbiota and RNA N6-methyladenosine modification in diabetic retinopathy.Frontiers in cell and developmental biology · 2026Review
- Astaxanthin Alleviates Intestinal Ferroptosis through Gut CommensalResearch (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Specific gut microbes are critically involved in the development of metabolic diseases, particularly obesity. Here, through analyses of diabetic patients and animal models, we identified Romboutsia ilealis as a novel gut bacterium that alleviates obesity and associated metabolic disorders by suppressing intestinal lipid absorption rather than altering energy expenditure. Metabolomic profiling revealed 2-oxoindole-3-acetate (OAA) as a key mediator of this effect, which was validated both in vitro and in vivo. Mechanistically, biotin-labeled OAA pull-down coupled with proteomics in the intestinal IPEC-J2 cells identified a direct interaction between OAA and the 26S proteasome subunit PSMD3, leading to destabilization of the m
Indexed as
Identifiers
41844893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.